News
BMY
43.99
+0.66%
0.29
Pharma R&D productivity seen improving for the first time in years - Deloitte
Healthcare Pharma R&D productivity seen improving for the first time in years - Deloitte. A new report from Deloite says productivity appears to have turned a corner in 2023. The internal rate of return from biopharma companies has been in decline since 2010.
Seeking Alpha · 19h ago
BMY June 14th Options Begin Trading
NASDAQ · 1d ago
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Bristol Myers Squb stock is considered to be a "vulnerable" stock. The company is expected to make a big move in the next few years. The stock has a strong correlation to the value of a company's stock. It's a good idea to look beyond the stock's value to see why a company is a good investment.
The Motley Fool · 2d ago
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
Bristol Myers Squibb's stock is down 35% from its 52-week high. But the company's dividend yield has increased by an average of 8% over the past five years. The pharmaceutical company is facing challenges, but there's still reason to like the stock. You'd have been better off investing in the S&P 500 instead of the company.
The Motley Fool · 2d ago
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
NASDAQ · 2d ago
Bristol-Myers Squibb: A Lost Decade?
Bristol-Myers Squibb's share price reached new all-time highs in 2022, driven by a strong pipeline and new approvals. However, doubts arose about the company's ability to close the patent gap and achieve growth. The company made several acquisitions, increasing its debt levels, but the long-term outlook remains uncertain. Valuation seems low enough to rate it still a strong buy.
Seeking Alpha · 2d ago
CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
CytomX Therapeutics, Inc. Is gearing up to release its Q1 2024 earnings results on May 8th of 2024. The company will also release phase 1a dose-escalation data for CX-904 for the treatment of solid tumors that express the EGFR mutation. The global solid tumor cancer treatment market size is estimated to reach $532.42 billion by 2032. CytomX is developing this drug in collaboration with Amgen.
Seeking Alpha · 2d ago
Schrodinger gets rights to cancer drug candidate back from Bristol
Schrodinger gets rights to cancer drug candidate back from Bristol. Bristol-Myers Squibb has returned the rights to a preclinical drug candidate to Schrodinger. The company had been conducting IND-enabling studies on the candidate. Bristol gained an SOS1 inhibitor in its recent acquisition of Mirati Therapeutics.
Seeking Alpha · 2d ago
Is Merck Stock Fully Valued At $130?
NASDAQ · 3d ago
Should You Pick Bristol Myers Squibb Stock At $45?
NASDAQ · 3d ago
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
NASDAQ · 3d ago
Pfizer Stock: Finally The Market Is Waking Up
Pfizer's Q1 2023 results beat market forecasts, with strong revenue growth and cost management improvements. The company expects continued growth from non-COVID drugs and anticipates significant revenue from Comirnaty and Paxlovid. Pfizer's stock is undervalued compared to its peers and offers a higher-than-average dividend.
Seeking Alpha · 3d ago
3 Blue-Chip Bargains Trading At 52-Week Lows
Three blue-chip stocks, Bristol-Myers, Zoetis, and Monster Beverage, are trading at 52-week lows. Bristol is trading at the best yield in 12 years and has 154% upside potential to fair value. The pharma giant faces one of the biggest patent cliffs in the industry.
Seeking Alpha · 3d ago
Editas, Bristol Myers extend T cell therapy collaboration
Healthcare Editas, Bristol Myers extend T cell therapy collaboration by two years to 2026. Under the partnership, Editas can develop genome-editing tools. Bristol Myers can opt-in to develop gene-edited alpha-beta T cell therapies. Editas will be eligible to receive milestone payments on new therapies.
Seeking Alpha · 3d ago
iShares MSCI USA Value Factor ETF -- Insider Buying Index Registering 10.9%
NASDAQ · 4d ago
Non-Farm Payrolls Preview For April 2024: 3 Major Considerations
April 2024 jobs report expected to show an increase of 250,000 jobs, indicating continued tightness in the labor market. Healthcare sector likely to add jobs, while drug manufacturers may struggle. Construction, government, energy, and beverage industries may see job decreases in April 2024. The S&P 500 lost 3.24% in March after the March 2024 non-farm payrolls report.
Seeking Alpha · 4d ago
Pfizer raises guidance amid cost savings
Seeking Alpha · 4d ago
Editas Medicine Announced A Two-year Extension To The Alpha-Beta T Cell Collaboration With Bristol Myers Squibb; The Extension Also Has Options To Extend The Collaboration For Up To An Additional Two Years
Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs are currently in IND-enabling studies. Editas Medicine may develop genome editing tools for development of gene edited T cell therapies. The company is eligible to receive tiered royalties on net sales.
Benzinga · 4d ago
Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Bristol-Myers Squibb's revenues exceeded analyst estimates by 3.6%. The company's shares are down 10% from a week ago. Earnings per share (EPS) missed estimates by 22%. Revenue is expected to decline by 1.5% in the next 3 years. The company has two warning signs for investors.
Simply Wall St · 4d ago
Hold Rating on Bristol-Myers Squibb Amid Earnings Uncertainty and Strategic Investments
TipRanks · 4d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.